Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Public ClinicalTrials.gov record NCT00122681. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age.
Study identification
- NCT ID
- NCT00122681
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 18,729 participants
Conditions and interventions
Conditions
Interventions
- Cervarix™ Biological
- Havrix™-based investigational formulation Biological
Biological
Eligibility (public fields only)
- Age range
- 15 Years to 25 Years
- Sex
- Female
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2004
- Primary completion
- Nov 2, 2006
- Completion
- Nov 25, 2009
- Last update posted
- Aug 19, 2018
2004 – 2009
United States locations
- U.S. sites
- 50
- U.S. states
- 24
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35233 | — |
| GSK Investigational Site | Fountain Valley | California | 92708 | — |
| GSK Investigational Site | San Diego | California | 92108 | — |
| GSK Investigational Site | San Francisco | California | 94115 | — |
| GSK Investigational Site | Boulder | Colorado | 80303 | — |
| GSK Investigational Site | Boulder | Colorado | 80304 | — |
| GSK Investigational Site | Denver | Colorado | 80218 | — |
| GSK Investigational Site | Louisville | Colorado | 80027 | — |
| GSK Investigational Site | Clearwater | Florida | 33759 | — |
| GSK Investigational Site | Coral Gables | Florida | 33134 | — |
| GSK Investigational Site | Miami | Florida | 33136 | — |
| GSK Investigational Site | West Palm Beach | Florida | 33409 | — |
| GSK Investigational Site | Augusta | Georgia | 30912 | — |
| GSK Investigational Site | Honolulu | Hawaii | 96826 | — |
| GSK Investigational Site | Iowa City | Iowa | 52242 | — |
| GSK Investigational Site | Arkansas City | Kansas | 67005 | — |
| GSK Investigational Site | Wichita | Kansas | 67205 | — |
| GSK Investigational Site | Wichita | Kansas | 67207 | — |
| GSK Investigational Site | Bardstown | Kentucky | 40004 | — |
| GSK Investigational Site | Louisville | Kentucky | 40202 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55455 | — |
| GSK Investigational Site | Omaha | Nebraska | 68131 | — |
| GSK Investigational Site | Lebanon | New Hampshire | 03756 | — |
| GSK Investigational Site | Morristown | New Jersey | 07960 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87131 | — |
| GSK Investigational Site | New York | New York | 10029 | — |
| GSK Investigational Site | Poughkeepsie | New York | 12601 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27514 | — |
| GSK Investigational Site | New Bern | North Carolina | 28562 | — |
| GSK Investigational Site | Cleveland | Ohio | 44109 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74105 | — |
| GSK Investigational Site | Portland | Oregon | 97210 | — |
| GSK Investigational Site | Carnegie | Pennsylvania | 15106 | — |
| GSK Investigational Site | Erie | Pennsylvania | 16502 | — |
| GSK Investigational Site | Erie | Pennsylvania | 16505 | — |
| GSK Investigational Site | Erie | Pennsylvania | 16507 | — |
| GSK Investigational Site | Erie | Pennsylvania | 16508 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19114 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15236 | — |
| GSK Investigational Site | Austin | Texas | 78705 | — |
| GSK Investigational Site | Houston | Texas | 77004 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | Webster | Texas | 77598 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84120 | — |
| GSK Investigational Site | Charlottesville | Virginia | 22903 | — |
| GSK Investigational Site | Spokane | Washington | 99202 | — |
| GSK Investigational Site | Spokane | Washington | 99218 | — |
| GSK Investigational Site | Vancouver | Washington | 98664 | — |
| GSK Investigational Site | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00122681, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00122681 live on ClinicalTrials.gov.